Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index

Diabetes, Obesity & Metabolism
Raffaella GentilellaPaolo Pozzilli

Abstract

To assess the relationship between baseline body mass index (BMI) and glycaemic control in dulaglutide-treated patients, a post hoc analysis was conducted on HbA1c and baseline BMI data from eight AWARD studies, with a total of 5770 patients. Changes from baseline in HbA1c data from patients treated with 1.5 mg or 0.75 mg dulaglutide, active comparator or placebo, were analyzed in each study (AWARD-1 to -6, -8 and - 9) at approximately 6 months (26, 24 and 28 weeks, respectively). Within each study, data were analyzed by the following baseline BMI categories: <30, ≥30 to <35, and ≥ 35 kg/m2 . In this post hoc analysis, 1.5 mg or 0.75 mg dulaglutide treatment achieved statistically significant HbA1c reductions from baseline in all BMI categories (least-squares mean change from -0.62 to -1.75%) across the AWARD studies. No statistically significant treatment-by-BMI category interactions were found for reductions in HbA1c. This post hoc analysis of eight AWARD studies indicates that baseline BMI does not affect the relative treatment efficacy of dulaglutide as measured by HbA1c change from baseline in any study. Dulaglutide is an effective treatment option for adult patients with type 2 diabetes regardless of their baseline BMI ca...Continue Reading

References

Oct 30, 2015·Diabetes, Obesity & Metabolism·Sten Madsbad
Sep 14, 2016·Diabetes Research and Clinical Practice·Helene BihanJonathan E Shaw
Mar 13, 2018·Acta Diabetologica·N SimioniUNKNOWN ReaL (NN2211-4118) Study Group*

❮ Previous
Next ❯

Citations

Apr 18, 2020·The Journal of Clinical Endocrinology and Metabolism·Mario Luca MorieriGian Paolo Fadini
Feb 1, 2020·Drugs·Lesley J Scott
Nov 19, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Mario Luca MorieriGian Paolo Fadini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.